Airways allergic inflammation and L. reuterii treatments in asthmatic children
Randomized, double-blind and placebo controlled trial of the effect of L. reuteri in children 6-14y with well-controlled asthma, on airway inflammation measured by certain inflammatory parameters, and clinically. L. reuteri or placebo was ingested during 60 days, with 22 in the active group and21 in the placebo group.
Compared to placebo L. reuteri significantly reduced airway inflammation, shown as changed levels in exhaled breath condensate:
• reduction of exhaled nitric oxide (FeNO)
• reduction of the cytokine IL-2
• increase of the cytokine IL-10
Bronchial airway inflammation was significantly reduced, without change in clinical parameters.
Miraglia del Giudice M, Maiello N, Decimo F, Fusco N, D’Agostino B, Sullo N, Capasso M, Salpietro V, Gitto E, Ciprandi G, Marseglia GL, Perrone L. Airways allergic inflammation and L. reuterii treatments in asthmatic children. J Biol Regul Homeost Agents. 2012;26(1, Suppl.):35(S)-40(S).